Cancer trials are getting harder to complete, suggesting a role for more powerful RWE, AI solutions

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Clinical trials for oncology drugs are running into unique challenges as protocols become more complex and as the number of new investigational agents continues to outpace all other drugs, according to a recent study by Tufts University researchers.

The study, “Protocol complexity and patient enrollment intensity challenges in oncology trials,” was conducted by Zachary Smith, a senior research analyst at Tufts, and led by Kenneth Getz, professor and director of the Tufts Center for the Study of Drug Development.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies. 
Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked. A study led by researchers at Washington University School of Medicine in St. Louis takes a deep dive into inherited cancer mutations measured in a healthy blood sample and reports how those mutations might take a toll on the body’s cells starting at birth, perhaps predisposing a person to develop cancers at various stages of life.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login